Stairway to Grey Peptide: What the Evidence Shows

Key Takeaways

• Compounds covered: Alpha-MSH analogs (palmitoyl tetrapeptide-20), K(D)PT, GHK-Cu
• Goal area: Hair repigmentation — slowing or reversing grey hair
• Evidence range: Ranges from case series (alpha-MSH agonist topicals) to in vitro human follicle data (K(D)PT) and mechanistic-only evidence (GHK-Cu for oxidative stress pathway)
• Regulatory range: All compounds in this article are either cosmetic ingredients or research-context only; none is FDA-approved for any hair pigmentation indication
• Key biomarkers for premature graying: Ferritin, vitamin B12, TSH, hs-CRP, comprehensive metabolic panel
• As of April 2026: No peptide compound is FDA-approved for hair repigmentation; the strongest published evidence is a case series of a topical alpha-MSH agonist (Trüeb et al., 2022)
• Bottom line: Reversal is plausible only in follicles with surviving melanocyte stem cells; age-related graying from irreversible MelSC depletion cannot be reversed by any currently available peptide.

Understanding Hair Graying: The Biology

Hair color is produced by melanocytes — pigment-producing cells that synthesize melanin and transfer it to the cortical keratinocytes of the growing hair shaft during anagen. The continued availability of pigment depends on a population of melanocyte stem cells (MelSCs) residing in the follicle bulge niche, which self-renew to replenish differentiated melanocytes with each hair cycle.

Nishimura and colleagues published the landmark 2005 Science paper establishing that graying results from progressive, irreversible MelSC loss from the bulge niche. That paper demonstrated that graying corresponds to incomplete MelSC maintenance in the niche — the stem cells differentiate prematurely rather than self-renewing, depleting the reservoir that would otherwise replenish melanocytes across successive hair cycles. A 2005 Cell Previews commentary by Steingrímsson and colleagues synthesized the mechanistic framework, identifying Pax3 and Mitf as key regulators of the balance between MelSC self-renewal and differentiation, and Sarin and Artandi's 2007 Stem Cell Reviews paper reviewed the evidence that MelSC loss is the irreversible step — once depleted, the stem cells are not regenerated.

The biochemical mechanism driving this depletion includes oxidative stress. Wood and colleagues, writing in the FASEB Journal in 2009, documented millimolar hydrogen peroxide accumulation in grey hair follicles due to loss of catalase activity, causing oxidative bleaching of newly synthesized melanin and damaging melanocyte DNA. This oxidative damage is now understood as a major contributor to both melanocyte apoptosis and MelSC depletion over time.

Jo and colleagues, in a 2018 Annals of Dermatology review, provided a complete mechanistic taxonomy of graying across three streams: MelSC exhaustion, melanocyte apoptosis, and defective melanin transfer. Each stream represents a potential intervention point — though the first, MelSC exhaustion, is the most difficult because it involves the loss of the regenerative reservoir itself.

Peptides are mechanistically relevant to hair color biology because they can potentially address melanocortin receptor signaling (which drives tyrosinase activity and melanin synthesis), oxidative stress (which accelerates melanocyte apoptosis and MelSC depletion), and inflammatory pathways (which disrupt normal follicular pigmentation). The critical question is whether any available peptide intervenes early enough and at sufficient scale to produce visible repigmentation in a hair follicle whose melanocyte stem cells are still viable.

Peptides Studied for Hair Repigmentation: A Quick Comparison

The following peptides have published evidence relevant to hair pigmentation or graying mechanisms. They are listed by strength of clinical evidence, from most to least studied in humans.

• Compound: Alpha-MSH agonist topicals (palmitoyl tetrapeptide-20)
  Mechanism for graying: Agonize MC1R on follicular melanocytes; stimulate tyrosinase activity and melanin synthesis; immunomodulate the scalp microenvironment
  Evidence: Case series (alpha-MSH agonist, partial repigmentation in premature graying patients); controlled study (palmitoyl tetrapeptide-20 for hair pigmentation)
  FDA status: Cosmetic ingredients; not FDA-approved as drugs for any indication
  SP availability: Not available through Superpower
  Route: Topical
• Compound: K(D)PT (alpha-MSH-derived tripeptide)
  Mechanism for graying: Stimulates human hair follicle melanocyte activity and pigment synthesis under proinflammatory conditions; protease-resistant MSH analog
  Evidence: In vitro / human hair follicle organ culture under inflammatory conditions
  FDA status: Not FDA-approved; research context only
  SP availability: Not available through Superpower
  Route: Research context only
• Compound: GHK-Cu (copper peptide)
  Mechanism for graying: Antioxidant gene-expression activity addresses oxidative burden on follicular melanocytes; anti-inflammatory properties in the follicular microenvironment; indirect mechanism
  Evidence: Mechanistic / in vitro only for hair pigmentation; no controlled repigmentation trials
  FDA status: Cosmetic ingredient (topical); compounded injectable is not FDA-approved for any indication and is subject to Section 503A compounding requirements (patient-specific prescription from a licensed prescriber required)
  SP availability: Availability of compounded injectable GHK-Cu through Superpower's licensed provider network depends on current FDA bulk drug substance categorization (see Regulatory Status below), provider evaluation, and current formulary status. As of April 2026, injectable GHK-Cu was removed from Category 2 of the interim 503A bulks list in the April 15, 2026 FDA action but was not added to Category 1; its compounding pathway under FDCA § 503A is pending PCAC review. Patients should confirm current availability directly with their provider.
  Route: Topical or subcutaneous injection

Compounds listed as "research context only" are not legally available by prescription in the US. Their inclusion is for educational context only.

Peptides Studied for Hair Repigmentation: Individual Profiles

Each compound interacts with hair pigmentation biology through a different mechanism. The evidence base, biological plausibility, and regulatory status differ substantially — they should not be evaluated as a single category.

Alpha-MSH agonist topicals (palmitoyl tetrapeptide-20 and related)

Alpha-melanocyte-stimulating hormone (alpha-MSH) is an endogenous neuropeptide that regulates melanocyte function through the melanocortin 1 receptor (MC1R). Abdel-Malek and colleagues, writing in Annals of the New York Academy of Sciences in 1999, established the MC1R-mediated pathway through which alpha-MSH stimulates tyrosinase activity and melanin synthesis in melanocytes — the pharmacological foundation for MSH analog peptide approaches to repigmentation. De Luca and colleagues, in a 1993 Journal of Cell Science study, established that alpha-MSH stimulates cultured human melanocytes through high-affinity receptor binding with dose-dependent proliferative effects.

Ito and colleagues, in a 2009 British Journal of Dermatology study, provided the most directly relevant human follicle evidence: K(D)PT (an alpha-MSH-related tripeptide) stimulated pigmentation in cultured human hair follicles under proinflammatory conditions — conditions that mimic stress- and inflammation-triggered graying. [In vitro / human follicle organ culture] This demonstrates that MSH-pathway stimulation in cultured human follicles can increase melanocyte activity when inflammatory suppression is the mechanism of dysfunction.

Trüeb and colleagues, in a 2022 case series published in the International Journal of Trichology, examined a topical alpha-MSH agonist preparation in premature graying patients and found partial pigment restoration — the strongest published clinical evidence for the "stairway to grey" product category. This is a case series, not a randomized controlled trial; controlled evidence for alpha-MSH agonist repigmentation in humans remains limited. Almeida Scalvino and colleagues' 2018 International Journal of Cosmetic Science study reported efficacy of the α-MSH agonist palmitoyl tetrapeptide-20 in hair pigmentation — providing supporting evidence for this compound class in hair pigmentation biology.

[Case series / Phase II for repigmentation; RCT for hair density] These compounds are regulated as cosmetic ingredients. They are available over the counter in topical formulations and do not require a prescription. They are not FDA-approved as drugs for any hair or pigmentation indication.

K(D)PT (alpha-MSH-derived tripeptide)

K(D)PT is a tripeptide structurally derived from the active core of alpha-MSH, with a D-lysine substitution in its preclinical characterization. Preclinical receptor-binding studies describe melanocyte-stimulating activity relevant to the MSH pathway. The Ito 2009 study was an in-vitro investigation using cultured human hair follicles under proinflammatory conditions; it was a mechanistic investigation, not a treatment study. [In vitro only] K(D)PT is not FDA-approved for any indication. It is not legally available by prescription in the United States, is not compounded under Section 503A, and is not available through Superpower. Its inclusion in this article is for mechanistic and educational context only. K(D)PT sold online as a "research chemical" is not legally authorized for human therapeutic use — the intended-use doctrine (21 CFR § 201.128) treats products marketed as "research use only" but used for human therapeutic purposes as unapproved new drugs — and research-use-only labeling does not provide a legal pathway for human consumption.

GHK-Cu and oxidative stress

GHK-Cu's proposed role in grey hair biology is mechanistic rather than directly demonstrated in repigmentation trials. The rationale derives from two intersecting findings. First, oxidative stress — specifically H2O2 accumulation from catalase loss — is a primary driver of melanocyte apoptosis and graying, as Wood 2009 documented. Seiberg, in a 2013 review in the International Journal of Cosmetic Science, characterized the multiple effects of oxidative stress in age-induced hair graying, showing how reactive oxygen species contribute to cumulative melanocyte damage and graying over time. Arck and colleagues, in a 2006 FASEB Journal paper, provided direct evidence of melanocyte apoptosis in aging hair follicles as an indicator of oxidative tissue damage.

Second, GHK-Cu modulates antioxidant gene expression. Pickart and Margolina's 2018 review documented GHK-Cu's anti-inflammatory and regenerative actions in skin tissue, and Pickart and colleagues' 2015 BioMed Research International review characterized GHK's antioxidant gene-expression effects across multiple cellular pathways. The plausible inference is that reducing oxidative burden in the follicular microenvironment could slow melanocyte apoptosis. No controlled human trial has tested this directly for repigmentation. [Mechanistic / in vitro for pigmentation indication]

The Biological Ceiling on Reversal

Understanding when peptide repigmentation is and is not biologically possible requires confronting what the MelSC research actually shows. Sarin and Artandi's 2007 Stem Cell Reviews review established that once MelSCs are depleted, graying is irreversible by any mechanism that does not restore the stem cell population. Lim and colleagues, in a 2013 Journal of Cutaneous and Aesthetic Surgery study, confirmed in human tissue that CD200-positive follicle stem cell depletion drives irreversible graying — moving the finding from mouse models into human follicle biology. Nishimura and colleagues' 2021 human follicle model paper further demonstrated that psychological stress accelerates this depletion through ectopic MelSC differentiation.

The practical implication is a biological ceiling: peptides that stimulate surviving melanocytes (alpha-MSH analogs) or reduce oxidative stress on remaining MelSCs (GHK-Cu) are only biologically plausible in follicles that still have viable pigment-producing capacity; controlled clinical evidence for actual repigmentation remains limited to case series. This is most likely in premature graying — where Desai and colleagues' 2025 review identifies oxidative stress, nutritional deficiency, and autoimmunity as the dominant reversible drivers — and least likely in age-related graying dominated by full MelSC depletion. Sîrbu and colleagues, in a 2022 cross-sectional study in Skin Pharmacology and Physiology, documented reduced melanogenic enzyme expression (tyrosinase, TYRP-1) in premature grey follicles, suggesting melanocyte dysfunction rather than full MelSC loss in this population — which may represent a more favorable target for peptide intervention.

Regulatory Status at a Glance

As of April 2026, the compounds discussed in this article carry the following regulatory statuses.

• Alpha-MSH agonist topicals (palmitoyl tetrapeptide-20): Cosmetic ingredients; not FDA-approved as drugs; regulated under FDA cosmetics law
• K(D)PT: Not FDA-approved for any indication; research context only; not legally available by prescription in the US
• GHK-Cu (topical cosmetic form): Cosmetic ingredient; not FDA-approved as a drug
• GHK-Cu (compounded injectable): Not FDA-approved for any indication. Injectable GHK-Cu was removed from Category 2 of the FDA interim 503A bulks list in the April 15, 2026 FDA action but was not added to Category 1; as of April 2026, its compounding pathway under FDCA § 503A is pending Pharmacy Compounding Advisory Committee (PCAC) review. Access to compounded injectable GHK-Cu depends on the individual compounding pharmacy's sourcing decisions in light of this evolving categorization. A patient-specific prescription from a licensed prescriber is required under Section 503A; GHK-Cu is not indicated or studied in randomized controlled trials for hair pigmentation

Considerations When Comparing Peptides for Grey Hair

The compounds above have different mechanisms, different evidence bases, and different targets within the graying biology. Direct comparison is limited because they have been studied using different endpoints in different populations.

Type of graying: Premature graying with identifiable triggers (oxidative stress, nutritional deficiency, inflammatory condition) represents a more plausible target population than age-related graying dominated by full MelSC depletion. A provider evaluation that establishes the likely mechanism of graying is the prerequisite for any discussion of peptide intervention.

Whether viable melanocyte stem cells remain: This is the foundational biological question. No clinical test currently available directly measures MelSC viability in the human scalp. Younger age, shorter duration of graying, and a history of stress-associated or nutritionally-associated onset are clinical proxies for higher likelihood of surviving stem cells, but they are not definitive.

Evidence quality: The strongest published evidence for repigmentation is a case series (Trüeb 2022), not a randomized controlled trial. This distinction is clinically significant — case series establish that something can happen in some patients, not that it reliably occurs across a defined population at a specific effect size. Provider discussions should reflect this uncertainty.

Regulatory status: All compounds in this category are cosmetic ingredients or research-context compounds — none is an FDA-approved drug for graying. The informed consent conversation should include that distinction.

This is not an exhaustive list of clinical considerations. A licensed dermatologist or provider should evaluate the specific clinical presentation before any compound is discussed seriously as an intervention for grey hair.

Safety Considerations

Topical cosmetic formulations of alpha-MSH analogs and GHK-Cu have a generally well-tolerated safety profile in the cosmetic literature, with rare contact sensitization as the most commonly reported concern. These are not FDA-evaluated drug products, however, so the safety information that exists derives from cosmetic ingredient testing rather than clinical trial safety monitoring.

Injectable GHK-Cu (compounded form) carries the standard risks of any subcutaneous injectable: injection site reactions, infection risk if preparation standards are inadequate, and unknown long-term safety at therapeutic doses. All compounded injectable peptides require a patient-specific prescription from a licensed prescriber, dispensing by a 503A-compliant (or 503B-registered) compounding pharmacy, and the substance must qualify under FDCA § 503A(b)(1)(A) — meaning it must have a USP/NF monograph, be a component of an FDA-approved drug, or appear on the FDA 503A bulks list. GHK-Cu's 503A bulks list status is currently under FDA review following its April 15, 2026 removal from Category 2, which affects pharmacy-level decisions on lawful compounding.

Contraindications that apply broadly to peptides in this category include:

• Pregnancy and breastfeeding — safety data for any topical or injectable peptide in this category during pregnancy is absent
• Known contact sensitization to copper (for GHK-Cu) — topical copper sensitization is rare but documented
• Active scalp inflammatory condition — addressing the inflammatory driver first is the evidence-supported approach before adding topical actives
• Hormone-sensitive conditions — alpha-MSH analogs interact with melanocortin receptor pathways that have systemic immunomodulatory effects; relevant clinical consideration for individuals with autoimmune conditions affecting the skin

For compound-specific safety profiles, review the individual compound pages or consult the prescribing provider.

What to Test Before Exploring Peptides for Grey Hair

For premature graying specifically, baseline biomarker testing identifies whether a correctable biological driver is present. For age-related graying, the same testing is useful to rule out treatable causes — with the understanding that age-related graying from MelSC depletion is unlikely to respond to any currently available peptide.

• Ferritin: Iron deficiency is a documented contributor to premature graying. Low ferritin is correctable with iron supplementation or dietary change and should be excluded as a driver before pursuing peptide approaches.
• Vitamin B12: B12 deficiency causes premature graying through impaired melanin synthesis. Testing vitamin B12 identifies a correctable nutritional cause that is more evidence-supported than any peptide intervention for this specific driver.
• TSH (thyroid-stimulating hormone): Autoimmune thyroid disease (Hashimoto's thyroiditis) accelerates MelSC loss and graying. A TSH baseline with thyroid antibodies screens for this association before peptide approaches are considered.
• hs-CRP (high-sensitivity C-reactive protein): Systemic inflammation is associated with accelerated graying through oxidative and immunological mechanisms. Testing hs-CRP provides an objective inflammatory marker that may explain accelerated onset and direct anti-inflammatory approaches, including whether GHK-Cu's antioxidant properties are mechanistically relevant.
• Comprehensive metabolic panel: Liver and kidney function baselines are relevant before any injectable compound. Nutritional markers within the CMP (albumin, glucose) also provide context for metabolic contributors to premature graying.
• Estradiol (for women): Hormonal changes including early menopause are associated with accelerated graying. A baseline estradiol is relevant in women with prematurely accelerating grey progression.

Ferritin, B12, and TSH together identify the three most common correctable causes of premature graying. Correcting these first — before any peptide approach — is the evidence-supported sequence. Testing before any peptide protocol also establishes a baseline against which to assess whether biology is changing over time. Superpower's guide to biomarker testing covers the principles behind this approach.

Access and Regulatory Context

All compounds discussed in this article are available as cosmetic topicals — over the counter, without a prescription. Alpha-MSH analog topical formulations (palmitoyl tetrapeptide-20 and similar) are available through cosmetic channels. GHK-Cu topical serums are widely available as skincare products.

Compounded injectable GHK-Cu requires a prescription and a licensed provider relationship. Availability of any specific compounded injectable peptide also depends on current FDA bulk drug substance categorization, which has evolved for several peptide compounds in recent years. The provider evaluation should include hair and scalp history, discussion of graying type and likely mechanism, and review of baseline biomarkers before any injectable is prescribed. Injectable peptides sold outside licensed pharmacy channels — including products labeled "research use only" or "not for human use" — lack pharmaceutical-grade manufacturing oversight and are treated by the FDA as unapproved new drugs when the intended use is human therapeutic administration (intended use doctrine, 21 CFR § 201.128). Such products should not be used for self-administration.

K(D)PT is research-context only and is not available by prescription in the US. Superpower does not facilitate access to it.

Understanding Your Baseline

Grey hair has multiple biological causes — oxidative stress, nutritional deficiency, inflammatory drivers, MelSC depletion, and genetic factors — and the peptides studied for repigmentation target a subset of these. Knowing which mechanism is relevant in your specific situation determines whether any peptide intervention has biological plausibility for you. That determination requires data, not guesswork.

That principle — test first, then decide — is central to Superpower's approach to preventive health. Whether a provider conversation leads toward a topical alpha-MSH formulation, a nutritional correction for low ferritin or B12, or an honest assessment that age-related MelSC depletion has already occurred, the starting point is the same: knowing what the biology actually shows.

IMPORTANT SAFETY INFORMATION

Alpha-MSH agonist topical formulations (including alpha-MSH analog topicals such as palmitoyl tetrapeptide-20) are cosmetic ingredients regulated under FDA cosmetics law. They are not evaluated or approved by the FDA to diagnose, treat, cure, or prevent any disease or medical condition. Any claim about reversing graying through a biological mechanism is not supported by FDA evaluation of the cosmetic product. These are not drug products.

K(D)PT is not approved by the FDA for any medical use. Research has been limited to in vitro studies in human hair follicle models. Its safety, efficacy, appropriate dosing, and long-term effects in humans have not been established. K(D)PT is not prescribed, compounded, or dispensed through Superpower. Its inclusion in this article is for educational context only.

GHK-Cu in topical cosmetic formulations is regulated as a cosmetic ingredient; cosmetic ingredients are not evaluated or approved by the FDA to diagnose, treat, cure, or prevent any disease. GHK-Cu in compounded injectable form is not FDA-approved for any indication. Injectable GHK-Cu was removed from Category 2 of the FDA interim 503A bulks list in the April 15, 2026 FDA action but was not added to Category 1; as of April 2026, its compounding pathway under FDCA § 503A is pending Pharmacy Compounding Advisory Committee review. Access to compounded injectable GHK-Cu depends on the individual compounding pharmacy's sourcing decisions in light of this evolving categorization; a patient-specific prescription from a licensed prescriber is required under Section 503A. It is not indicated for hair repigmentation. As a compounded drug, it is not equivalent to any FDA-approved product.

No peptide compound discussed in this article is FDA-approved for reversing grey hair or hair repigmentation. This content is not a substitute for medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. Individual responses to any intervention depend on the specific mechanism of graying, which requires clinical evaluation to assess.

Full information on FDA-approved medications at dailymed.nlm.nih.gov.